Faron Pharmaceuticals’ management said the company is advancing its lead immunotherapy candidate bexmarilimab (anti-Clever-1) after showing 30% to 40% disease control rates in four late-line cancer cohorts: cutaneous melanoma, gastric cancer, cholangiocarcinoma and hepatocellular carcinoma. The team highlighted a newly validated companion diagnostic to measure Clever-1 in tumor samples and noted plans to optimize dosing frequency, expand selected cohorts toward pivotal discussions with regulators, and begin additional studies including neo-adjuvant and hematologic malignancy trials. Management also reported progress in the COVID-19 Hibiscus trial of Traumakine versus dexamethasone, supported by a US$6.1 million U.S. Department of Defense commitment, and said the first patient has been enrolled.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.